You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | "-B"生物科技股全線上揚,信達生物-B大升近10%
uSMART友信智投 06-01 12:15

uSMART友信智投6月1日消息,週一港股,市場再度熱炒"-B"生物科技股,17隻"-B"全線上揚,升幅高達0.96%-10%,截至北京時間11時39分,信達生物-B大升9.93%,啟明醫療-B大升8.04%,康方生物-B大升6.04%,康希諾生物-B、基石藥業-B、沛嘉醫療-B、開拓藥業-B大升逾5%,君實生物-B大升4.68%。

消息面上,信達生物-B(01801)和禮來製藥(LLY.US)共同宣佈在第56屆美國臨床腫瘤學會年會(ASCO)上通過壁報討論的形式公佈了雙方共同開發的信迪利單抗二線治療局部晚期或轉移性食管鱗癌(ORIENT-2)的關鍵臨床研究結果。

5月27日的《港股前瞻》曾指出,亞洲醫療類股是為數不多的幾個收復衛生事件引發的估值跌幅的板塊之一。一個追蹤指標顯示基於明年預期收益的市盈率為26倍,接近2018年以來最高水準,而MSCI亞太指數的市盈率為14倍。摩根資產管理的基金經理Joanna Kwok表示,選擇性的亞洲醫療股依然非常有吸引力,因為衛生事件引發了需求並放大了現有的結構趨勢。整體上港股生物醫療板塊強勢依舊,趁恒生指數低迷,場外資金更是對其虎視眈眈,尤其“-B”字頭板塊值得長期跟蹤。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account